Clin Mol Hepatol.
2023 Oct;29(4):969-972. 10.3350/cmh.2023.0359.
From nonalcoholic steatohepatitis, metabolic dysfunction-associated fatty liver disease, to steatotic liver disease: Updates of nomenclature and impact on clinical trials
- Affiliations
-
- 1School of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan
- 2Hepatobiliary Division, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan
- 3School of Medicine, College of Medicine and Center of Excellence for Metabolic Associated Fatty Liver Disease, National Sun Yat-sen University, Kaohsiung, Taiwan
- KMID: 2546381
- DOI: http://doi.org/10.3350/cmh.2023.0359
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Waiting for the changes after the adoption of steatotic liver disease
- Critical appraisal of metabolic dysfunction-associated steatotic liver disease: Implication of Janus-faced modernity
- Similar respiratory function including chronic obstructive pulmonary disease between non-alcoholic fatty liver disease and metabolic dysfunction-associated steatotic liver disease
- Nonalcoholic Steatohepatitis
- Changing the nomenclature from nonalcoholic fatty liver disease to metabolic dysfunction-associated fatty liver disease is more than a change in terminology
